FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit
The company reported an impressive over 11 times growth in net profit for the second quarter of FY25, with Profit After Tax (PAT) reaching Rs 17.94 crore compared to Rs 1.61 crore in the same period last year.
Shilpa Medicare Ltd reported an impressive over 11 times growth in net profit for the second quarter of FY25, with Profit After Tax (PAT) reaching Rs 17.94 crore compared to Rs 1.61 crore in the same period last year. On Thursday, shares of Shilpa Medicare surged by 5.66 per cent to Rs 871.55 from the previous closing of Rs 824.85.
Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) significantly increased their holdings in Shilpa Medicare during Q2 of FY25. FIIs added 4,90,977 shares, raising their stake to 9.59 per cent from 9.08 per cent in June 2024. Similarly, DIIs acquired 5,63,162 shares, increasing their stake to 8.18 per cent, up from 7.61 per cent in June 2024.
Financial Performance
For Q2 FY25 (on a year-on-year basis), the company's consolidated revenue from operations rose by 9.8 per cent to Rs 343.8 crore, up from Rs 312.98 crore. Additionally, EBITDA saw a substantial 42.7 per cent increase, reaching Rs 86 crore, while the EBITDA margin expanded by 570 basis points to 25 per cent from 19.3 per cent in the previous year.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
About the company
Shilpa Medicare, founded in 1987 and publicly listed in 1995, is promoted by Vishnukant Bhutada. The company specializes in manufacturing niche Active Pharmaceutical Ingredients (APIs), intermediates, and formulations, with contract research and manufacturing services also forming a key part of its operations. Shilpa Medicare has grown into a fully integrated pharmaceutical entity, operating seven facilities (six in India and one in Austria) and managing three R&D centers. The company’s formulation portfolio includes 16 injectable dosage forms and 19 oral solid dosage forms under Shilpa Medicare Ltd, and 13 formulations through its subsidiary, Shilpa Therapeutics.
Shilpa Medicare's stock has delivered strong returns, showing an impressive year-to-date gain of 164.78 per cent. Over the past year, the stock is up by 135.57 per cent. The company currently has a market capitalization of Rs 8,522.97 crore.
Disclaimer: This article is for informational purposes only and not investment advice.